1
|
Egorova A, Salina EG, Makarov V. Targeting Non-Replicating Mycobacterium tuberculosis and Latent Infection: Alternatives and Perspectives (Mini-Review). Int J Mol Sci 2021; 22:ijms222413317. [PMID: 34948114 PMCID: PMC8707483 DOI: 10.3390/ijms222413317] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Revised: 12/07/2021] [Accepted: 12/08/2021] [Indexed: 01/02/2023] Open
Abstract
Latent tuberculosis infection (LTBI) represents a major challenge to curing TB disease. Current guidelines for LTBI management include only three older drugs and their combinations-isoniazid and rifamycins (rifampicin and rifapentine). These available control strategies have little impact on latent TB elimination, and new specific therapeutics are urgently needed. In the present mini-review, we highlight some of the alternatives that may potentially be included in LTBI treatment recommendations and a list of early-stage prospective small molecules that act on drug targets specific for Mycobacterium tuberculosis latency.
Collapse
Affiliation(s)
- Anna Egorova
- The Federal Research Centre “Fundamentals of Biotechnology” of the Russian Academy of Sciences (Research Center of Biotechnology RAS), 119071 Moscow, Russia; (A.E.); (E.G.S.)
| | - Elena G. Salina
- The Federal Research Centre “Fundamentals of Biotechnology” of the Russian Academy of Sciences (Research Center of Biotechnology RAS), 119071 Moscow, Russia; (A.E.); (E.G.S.)
- Department of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, 27100 Pavia, Italy
| | - Vadim Makarov
- The Federal Research Centre “Fundamentals of Biotechnology” of the Russian Academy of Sciences (Research Center of Biotechnology RAS), 119071 Moscow, Russia; (A.E.); (E.G.S.)
- Correspondence:
| |
Collapse
|
2
|
Raphoko LA, Lekgau K, Lebepe CM, Leboho TC, Matsebatlela TM, Nxumalo W. Synthesis of novel quinoxaline-alkynyl derivatives and their anti-Mycobacterium tuberculosis activity. Bioorg Med Chem Lett 2021; 35:127784. [PMID: 33422606 DOI: 10.1016/j.bmcl.2021.127784] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Revised: 12/29/2020] [Accepted: 01/03/2021] [Indexed: 11/26/2022]
Abstract
The study report on the synthesis of a series of novel quinoxaline-alkynyl derivatives that were evaluated for their activity against Mycobacterium tuberculosis (Mtb) H37RV strain. A total of 19 compounds bearing an alcohol, aldehyde, mesylate and ester groups on the alkynly group, and also containing a chloro and nitro groups at the 6-position, were prepared. Seven compounds (3c, 4a-b, 5a, 5c, 6c and 6i), were found to have MIC90 < 10 µM, while five compounds (3b, 6a, 6b, 6d and 6h) had MIC90 in the range 10-20 µM. Compounds bearing a nitro substituent in the 6-position were generally more active and demonstrated a better safety profile, when compared to the unsubstituted and 6-chloro derivatives. Of the seven most active compounds, four contained nitro group at the 6-position.
Collapse
Affiliation(s)
- Lerato A Raphoko
- Department of Chemistry, Faculty of Science and Agriculture, University of Limpopo, Private Bag X1106, Sovenga 0727, South Africa
| | - Karabo Lekgau
- Department of Chemistry, Faculty of Science and Agriculture, University of Limpopo, Private Bag X1106, Sovenga 0727, South Africa
| | - Charity M Lebepe
- Department of Chemistry, Faculty of Science and Agriculture, University of Limpopo, Private Bag X1106, Sovenga 0727, South Africa
| | - Tlabo C Leboho
- Department of Chemistry, Faculty of Science and Agriculture, University of Limpopo, Private Bag X1106, Sovenga 0727, South Africa
| | - Thabe M Matsebatlela
- Department of Biochemistry, Microbiology and Biotechnology, Faculty of Science and Agriculture, University of Limpopo, Private Bag X1106, Sovenga 0727, South Africa
| | - Winston Nxumalo
- Department of Chemistry, Faculty of Science and Agriculture, University of Limpopo, Private Bag X1106, Sovenga 0727, South Africa.
| |
Collapse
|
3
|
Antimicrobial activity of IDD-B40 against drug-resistant Mycobacterium tuberculosis. Sci Rep 2021; 11:740. [PMID: 33436895 PMCID: PMC7804135 DOI: 10.1038/s41598-020-80227-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Accepted: 12/17/2020] [Indexed: 01/30/2023] Open
Abstract
The emergence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis creates the urgency for new anti-tuberculosis drugs to improve the efficiency of current tuberculosis treatment. In the search for a new potential tuberculosis drug, we synthesized an isoindole based chemical library and screened a potential candidate with significant anti-tuberculosis activity. The compound named 2-hydroxy-4-(4-nitro-1,3-dioxoisoindolin-2-yl) benzoic acid (IDD-B40) showed strong activity against all the tested drug-susceptible and drug-resistant strains of M. tuberculosis, with the 50% minimum inhibitory concentrations (MIC50) of 0.39 μg/ml both in culture broth and inside Raw 264.7 cells. Also, IDD-B40, in combination with rifampicin, exhibited a direct synergistic effect against both XDR and H37Rv M. tuberculosis. Besides, IDD-B40 showed a better post-antibiotic effect (PAE) than did some first-line drugs and showed no significant cytotoxicity to any cell line tested, with a selectivity index of ≥ 128. Although IDD-B40 showed a result similar to isoniazid in the preliminary mycolic acid inhibition assay, it did not exhibit any effect against other mycolic acid-producing nontuberculous mycobacterial strains (NTM), and different non-mycobacterial pathogenic strains, so further studies are required to confirm the mode of action of IDD-B40. Considering its results against M. tuberculosis, IDD-B40 is a potential anti-tuberculosis drug candidate. However, further studies are required to evaluate its potential in vivo effect and therapeutic potential.
Collapse
|
4
|
Structural Modifications of 3-Triazeneindoles and Their Increased Activity Against Mycobacterium tuberculosis. Antibiotics (Basel) 2020; 9:antibiotics9060356. [PMID: 32599854 PMCID: PMC7344711 DOI: 10.3390/antibiotics9060356] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Revised: 06/17/2020] [Accepted: 06/18/2020] [Indexed: 02/01/2023] Open
Abstract
We synthesized 100 novel indole-based compounds with polyaza-functionalities, including 3-triazeneindoles, and tested their activity in vitro against laboratory M. tuberculosis H37Rv and clinical izoniazid-resistant CN-40 isolates, using gross and fine titration approaches. Here we present a few 3-triazeneindoles with the highest anti-mycobacterial activity. Introduction of short lipid tails into the 3-triazeneindole core additionally increased their activity against mycobacteria engulfed by murine macrophages. We also demonstrate that the compound TU112, one of the most active in our previous study, being not bioavailable after administration in mice per os, manifests prominent anti-mycobacterial activity after intravenous or aerosol delivery, as assessed by the mouse serum and lung supernatant titration assays.
Collapse
|
5
|
Islam MI, Han CM, Seo H, Kim S, Mahmud HA, Nam KW, Lee BE, Sadu VS, Lee KI, Song HY. In vitro activity of DNF-3 against drug-resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 2019; 54:69-74. [DOI: 10.1016/j.ijantimicag.2019.02.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Revised: 02/13/2019] [Accepted: 02/16/2019] [Indexed: 10/27/2022]
|
6
|
Kim S, Seo H, Mahmud HA, Islam MI, Lee BE, Cho ML, Song HY. In vitro activity of collinin isolated from the leaves of Zanthoxylum schinifolium against multidrug- and extensively drug-resistant Mycobacterium tuberculosis. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2018; 46:104-110. [PMID: 30097109 DOI: 10.1016/j.phymed.2018.04.029] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/01/2017] [Revised: 03/14/2018] [Accepted: 04/15/2018] [Indexed: 06/08/2023]
Abstract
BACKGROUND Tuberculosis is a very serious infectious disease that threatens humanity, and the emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR) strains resistant to drugs suggests that new drug development is urgent. In order to develop new tuberculosis drug, we have conducted in vitro anti-tubercular tests on thousands of plant-derived substances and finally found collinin extracted from the leaves of Zanthoxylum schinifolium, which has an excellent anti-tuberculosis effect. PURPOSE To isolate an anti-tubercular bioactive compound from the leaves of Z. schinifolium and evaluate whether this agent demonstrates any potential in vitro characteristics suitable for the development of future anti-tubercular drugs to treat MDR and XDR Mycobacterium tuberculosis. METHODS The methanolic extracts of the leaves of Z. schinifolium were subjected to bioassay-guided fractionation against M. tuberculosis using a microbial cell viability assay. In addition, following cell cytotoxicity assay, an intracellular anti-mycobacterial activity of the most active anti-tubercular compound was investigated after it was purified. RESULTS The active compound with anti-tubercular activity isolated from leaves of Z. schinifolium was identified as a collinin. The extracted collinin showed anti-tubercular activity against both drug-susceptible and -resistant strains of M. tuberculosis at 50% minimum inhibitory concentrations (MIC50s) of 3.13-6.25 µg/ml in culture broth and MIC50s of 6.25-12.50 µg/ml inside Raw264.7 and A549 cells. Collinin had no cytotoxicity against human lung pneumocytes up to a concentration of 100 µg/ml (selectivity index > 16-32). CONCLUSIONS Collinin extracted from the leaves of Z. schinifolium significantly inhibits the growth of MDR and XDR M. tuberculosis in the culture broth. In addition, it also inhibits the growth of intracellular drug-susceptible and drug-resistant tuberculosis in Raw264.7 and A549 cells. To our knowledge, this is the first report on the in vitro anti-tubercular activity of collinin, and our data suggest collinin as a potential drug to treat drug-resistant tuberculosis. Further studies are warranted to assess the in vivo efficacy and therapeutic potential of collinin.
Collapse
Affiliation(s)
- Sukyung Kim
- Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan, Chungnam 31151, South Korea
| | - Hoonhee Seo
- Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan, Chungnam 31151, South Korea
| | - Hafij Al Mahmud
- Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan, Chungnam 31151, South Korea
| | - Md Imtiazul Islam
- Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan, Chungnam 31151, South Korea
| | - Byung-Eui Lee
- Department of Chemistry, School of Life Sciences, Soonchunhyang University, Asan, Chungnam 31538, South Korea
| | - Myoung-Lae Cho
- National Development Institute of Korean Medicine, Gyeongsan, Gyeongnam 38540, South Korea
| | - Ho-Yeon Song
- Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan, Chungnam 31151, South Korea.
| |
Collapse
|
7
|
Seo H, Kim S, Mahmud HA, Islam MI, Nam KW, Lee BE, Lee H, Cho ML, Shin HM, Song HY. In vitroAntitubercular Activity of 3-Deoxysappanchalcone Isolated From the Heartwood ofCaesalpinia sappanLinn. Phytother Res 2017; 31:1600-1606. [DOI: 10.1002/ptr.5890] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2017] [Revised: 07/06/2017] [Accepted: 07/18/2017] [Indexed: 11/11/2022]
Affiliation(s)
- Hoonhee Seo
- Department of Microbiology and Immunology, School of Medicine; Soonchunhyang University; Cheonan Chungnam 31151 South Korea
| | - Sukyung Kim
- Department of Microbiology and Immunology, School of Medicine; Soonchunhyang University; Cheonan Chungnam 31151 South Korea
| | - Hafij Al Mahmud
- Department of Microbiology and Immunology, School of Medicine; Soonchunhyang University; Cheonan Chungnam 31151 South Korea
| | - Md Imtiazul Islam
- Department of Microbiology and Immunology, School of Medicine; Soonchunhyang University; Cheonan Chungnam 31151 South Korea
| | - Kung-Woo Nam
- Department of Life Science and Biotechnology; Soonchunhyang University; Asan Chungnam 31538 South Korea
| | - Byung-Eui Lee
- Department of Chemistry; Soonchunhyang University; Asan Chungnam 31538 South Korea
| | - Hanna Lee
- National Development Institute of Korean Medicine; Gyeongsan Gyeongnam 38540 South Korea
| | - Myoung-Lae Cho
- National Development Institute of Korean Medicine; Gyeongsan Gyeongnam 38540 South Korea
| | - Heung-Mook Shin
- National Development Institute of Korean Medicine; Gyeongsan Gyeongnam 38540 South Korea
- Department of Physiology; College of Korean Medicine Dongguk University; Gyeongju 780-714 Republic of Korea
| | - Ho-Yeon Song
- Department of Microbiology and Immunology, School of Medicine; Soonchunhyang University; Cheonan Chungnam 31151 South Korea
| |
Collapse
|
8
|
Seo H, Kim M, Kim S, Mahmud HA, Islam MI, Nam KW, Cho ML, Kwon HS, Song HY. In vitro activity of alpha-viniferin isolated from the roots of Carex humilis against Mycobacterium tuberculosis. Pulm Pharmacol Ther 2017; 46:41-47. [PMID: 28782713 DOI: 10.1016/j.pupt.2017.08.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Accepted: 08/03/2017] [Indexed: 10/19/2022]
Abstract
This study explores the antitubercular activity of α-viniferin, a bioactive phytochemical compound obtained from Carex humilis. α-Viniferin was active against both drug-susceptible and -resistant strains of Mycobacterium tuberculosis at MIC50s of 4.6 μM in culture broth medium and MIC50s of 2.3-4.6 μM inside macrophages and pneumocytes. In combination with streptomycin and ethambutol, α-viniferin exhibited an additive effect and partial synergy, respectively, against M. tuberculosis H37Rv. α-Viniferin also did not show cytotoxicity in any of the cell lines tested up to a concentration of 147 μM, which gives this compound a selectivity index of >32. Moreover, α-viniferin was active against 3 Staphylococcus species, including methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), and methicillin-resistant Staphylococcus epidermidis (MRSE).
Collapse
Affiliation(s)
- Hoonhee Seo
- Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan, Chungnam 31151, Republic of Korea
| | - Mijung Kim
- Regional Innovation Center, Soonchunhyang University, Asan, Chungnam 31538, Republic of Korea
| | - Sukyung Kim
- Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan, Chungnam 31151, Republic of Korea
| | - Hafij Al Mahmud
- Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan, Chungnam 31151, Republic of Korea
| | - Md Imtiazul Islam
- Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan, Chungnam 31151, Republic of Korea
| | - Kung-Woo Nam
- Department of Life Science and Biotechnology, Soonchunhyang University, Asan, Chungnam 31538, Republic of Korea
| | - Myoung-Lae Cho
- National Development Institute of Korean Medicine, Gyeongsan, Gyeongnam 38540, Republic of Korea
| | - Hyun-Sook Kwon
- National Development Institute of Korean Medicine, Gyeongsan, Gyeongnam 38540, Republic of Korea
| | - Ho-Yeon Song
- Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan, Chungnam 31151, Republic of Korea.
| |
Collapse
|
9
|
New 1-hydroxy-2-thiopyridine derivatives active against both replicating and dormant Mycobacterium tuberculosis. J Infect Chemother 2017; 23:794-797. [PMID: 28527650 DOI: 10.1016/j.jiac.2017.04.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 04/19/2017] [Accepted: 04/22/2017] [Indexed: 11/23/2022]
Abstract
Tuberculosis (TB) treatment is confounded by the range of metabolic states displayed by Mycobacterium tuberculosis, by the long duration required and by the increasing prevalence of drug-resistant strains. Latent TB infection is especially difficult to treat due to the phenotypic antibiotic resistance of non-replicating M. tuberculosis. Therefore, the development of new drugs effective against both active and latent TB infection is needed. New 1-hydroxy-2-thiopyridine derivatives were synthesized and found to be highly effective in vitro against both actively growing and dormant non-culturable M. tuberculosis. Such compounds are leads for the development of new drugs for all forms of TB including latent infection.
Collapse
|